Immix Biopharma (IMMX) News Today $2.03 -0.07 (-3.33%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$2.02 0.00 (-0.25%) As of 05/5/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Immix Biopharma (IMMX) to Release Earnings on ThursdayImmix Biopharma (NASDAQ:IMMX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-immix-biopharma-inc-stock/)May 3 at 3:08 AM | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 44.8% in AprilImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 191,300 shares, a drop of 44.8% from the March 31st total of 346,800 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average trading volume of 59,500 shares, the days-to-cover ratio is currently 3.2 days.May 1, 2025 | marketbeat.comImmix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025April 23, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPSImmix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09.March 27, 2025 | marketbeat.comImmix Biopharma (IMMX) Projected to Post Quarterly Earnings on ThursdayImmix Biopharma (NASDAQ:IMMX) will be releasing earnings on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comImmix Biopharma stock holds $7 target, Buy rating at H.C. WainwrightFebruary 11, 2025 | msn.comImmix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL AmyloidosisFebruary 11, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Immix Biopharma (NASDAQ:IMMX)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Immix Biopharma in a research report on Monday.February 10, 2025 | marketbeat.comBuy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201February 10, 2025 | tipranks.comImmix Biopharma, Inc. Receives FDA RMAT Designation for CAR-T Therapy NXC-201 in Relapsed/Refractory AL AmyloidosisFebruary 10, 2025 | quiverquant.comImmix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL AmyloidosisFebruary 10, 2025 | globenewswire.comSeveral Insiders Invested In Immix Biopharma Flagging Positive NewsFebruary 5, 2025 | finance.yahoo.comShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 11.0%Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 356,500 shares, a decrease of 11.0% from the December 15th total of 400,500 shares. Approximately 2.2% of the company's stock are short sold. Based on an average daily volume of 165,700 shares, the short-interest ratio is currently 2.2 days.January 19, 2025 | marketbeat.comFY2024 EPS Forecast for Immix Biopharma Decreased by AnalystImmix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Equities researchers at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Immix Biopharma in a research note issued to investors on Monday, January 6th. HC Wainwright analyst R. Burns now forecasts that the companyJanuary 9, 2025 | marketbeat.comImmix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201January 8, 2025 | markets.businessinsider.comImmix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-TJanuary 7, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)January 6, 2025 | markets.businessinsider.comImmix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a research report on Monday.January 6, 2025 | marketbeat.comImmix Biopharma Reports Positive Early Results From NEXICART-2 Trial Of NXC-201 In AL AmyloidosisDecember 19, 2024 | markets.businessinsider.comImmix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) AmyloidosisDecember 19, 2024 | globenewswire.comImmix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 19, 2024 | finanznachrichten.deImmix Biopharma reports promising CAR-T therapy resultsDecember 19, 2024 | uk.investing.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in NovemberImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 470,700 shares, a growth of 17.5% from the November 15th total of 400,700 shares. Currently, 2.9% of the company's stock are sold short. Based on an average trading volume of 159,400 shares, the days-to-cover ratio is presently 3.0 days.December 16, 2024 | marketbeat.comJournal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 16, 2024 | globenewswire.comImmix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024December 10, 2024 | globenewswire.comWill Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?December 10, 2024 | uk.finance.yahoo.comImmix Biopharma to Host Conference Call for Investors, Analysts and Members of the MediaDecember 9, 2024 | globenewswire.comImmix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis PatientsNovember 25, 2024 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comImmix Biopharma’s Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial OutlookOctober 3, 2024 | markets.businessinsider.comImmix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2October 2, 2024 | globenewswire.comImmix Biopharma gains AL Amyloidosis expert for advisory boardSeptember 22, 2024 | investing.comImmix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory BoardSeptember 19, 2024 | globenewswire.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest UpdateImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 324,000 shares, a decline of 43.0% from the August 15th total of 568,400 shares. Based on an average daily volume of 154,100 shares, the short-interest ratio is currently 2.1 days. Approximately 2.0% of the company's shares are short sold.September 14, 2024 | marketbeat.comImmix Biopharma Independent Director Acquires 2.6% More StockAugust 29, 2024 | finance.yahoo.comImmix Biopharma, Inc.: Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2August 29, 2024 | finanznachrichten.deImmix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2August 28, 2024 | globenewswire.comHC Wainwright Weighs in on Immix Biopharma, Inc.'s Q3 2024 Earnings (NASDAQ:IMMX)Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - HC Wainwright boosted their Q3 2024 earnings per share estimates for Immix Biopharma in a report issued on Monday, August 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.16) per share for the quarterAugust 21, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in StockAugust 20, 2024 | insidertrades.comFY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. ResImmix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Stock analysts at Edison Inv. Res lifted their FY2024 earnings per share estimates for Immix Biopharma in a research report issued on Wednesday, August 14th. Edison Inv. Res analyst S. Romanoff now anticipates that the company will post earningsAugust 19, 2024 | marketbeat.comIMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024August 12, 2024 | msn.comImmix Biopharma, Inc. (NASDAQ:IMMX) Director Jason Hsu Acquires 6,000 SharesAugust 1, 2024 | insidertrades.comBuy Rating Affirmed: NXC-201’s Promising Clinical Trials and Strategic CIRM Grant Propel Positive OutlookJuly 27, 2024 | markets.businessinsider.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 25, 2024 | globenewswire.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 25, 2024 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for Immix Biopharma (NASDAQ:IMMX)HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Immix Biopharma in a research note on Tuesday.July 9, 2024 | marketbeat.comImmix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201July 8, 2024 | globenewswire.comImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Increase in Short InterestImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 473,100 shares, a growth of 39.7% from the May 31st total of 338,700 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily trading volume, of 131,400 shares, the days-to-cover ratio is presently 3.6 days.July 1, 2024 | marketbeat.comImmix Biopharma (NASDAQ:IMMX) Now Covered by HC WainwrightHC Wainwright assumed coverage on shares of Immix Biopharma in a report on Monday. They issued a "buy" rating and a $7.00 price target on the stock.July 1, 2024 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.6% in MayImmix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 338,700 shares, a decline of 7.6% from the May 15th total of 366,500 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average daily volume of 134,900 shares, the short-interest ratio is currently 2.5 days.June 17, 2024 | marketbeat.com Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMX Media Mentions By Week IMMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMX News Sentiment▼0.940.72▲Average Medical News Sentiment IMMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMX Articles This Week▼21▲IMMX Articles Average Week Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CARGO Therapeutics News Today Amarin News Today Aardvark Therapeutics News Today Annexon News Today Ocugen News Today enGene News Today Gossamer Bio News Today DiaMedica Therapeutics News Today Inventiva News Today MediWound News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMMX Stock Free IMMX Stock Alerts